Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Single-arm, Phase 3b Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Participants With Severe Asthma on High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Long-term Oral Corticosteroid Therapy (WAYFINDER)

Trial Profile

A Multicentre, Single-arm, Phase 3b Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Participants With Severe Asthma on High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Long-term Oral Corticosteroid Therapy (WAYFINDER)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tezepelumab (Primary) ; Prednisolone; Prednisone
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms WAYFINDER
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 13 May 2025 According to AstraZeneca media release, data from the study will be presented at at the American Thoracic Society (ATS) International Conference, in San Francisco, CA from May 16 to 21, 2025.
  • 23 Oct 2024 Status changed from active, no longer recruiting to completed.
  • 23 Aug 2023 Planned End Date changed from 12 Jul 2024 to 12 Sep 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top